LIXIANA TABLETS 15mg100c 抗血栓药 盐酸依度沙班片 [0114987081102706]
Price: US$519.35(tax included)
List Price: US$623.20
Weight: 40g
Item description
The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment. | |||||||||
| |||||||||
Effects of this medicineThis medicine suppresses blood coagulation by inhibiting activated blood coagulation factor X in the coagulation pathway. It suppresses blood coagulation, improves blood coagulation tendency, and prevents or treats, disease (thromboembolism) caused by blood coagulation in blood vessels. It is usually used for treatment and prevention of the recurrence of venous thromboembolism (deep venous thrombosis and pulmonary thromboembolism). | |||||||||
Before using this medicine, be sure to tell your doctor and pharmacist
| |||||||||
Dosing schedule (How to take this medicine)
| |||||||||
Precautions while taking this medicine | |||||||||
Possible adverse reactions to this medicineThe most commonly reported adverse reactions include nasal bleeding and hypermenorrhea. If any of these symptoms occur, consult with your doctor or pharmacist. The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.
The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above. | |||||||||
Storage conditions and other information
|
简介:
商品名:LIXIANA TABLETS
英文名:Edoxaban Tosilate Hydrate
中文名:依度沙班片
生产商:第一三共
リクシアナ錠15mg/
药物分类名称
口服FXa抑制剂
批准日期:2011年7月
商標名
LIXIANA TABLETS
药效药理
1. 作用机序
依度沙班在体外竞争性和选择性地竞争性地抑制人活化凝血因子X(FXa)。 其他凝血因子如凝血酶对丝氨酸蛋白酶的抑制活性较弱。
2. 抗凝固作用
Edoxaban在体外延长了人血浆中的PT,APTT和凝血酶时间(TT)。凝固时间延长效应的强度按PT> APTT> TT的顺序排列。
3. 血栓模型中的抗血栓形成作用
在大鼠静脉血栓形成模型中,静脉充血血栓模型,动静脉分流模型和组织因子诱导DIC模型,依度沙班通过单次口服给药剂量依赖性地抑制血栓形成。 在大鼠静脉血栓形成模型中,埃托沙班延长PT,而不影响APTT,剂量显示抗血栓形成作用。
4. 止血效果
在大鼠尾巴出血模型中,较高剂量的依沙班,华法林和依诺肝素比抗血栓剂量显着延长出血时间。 对于依诺沙班,大鼠静脉血栓形成模型中出血时间2倍延长剂量(BT2)与血栓形成50%抑制剂量(ED 50)的比值(BT 2/ED 50)较高,为依诺肝素。
5. 凝血因子制剂抗凝效果
在人血浆中的体外PT延长作用被重组活化凝血因子VII,凝血因子抗体旁路活化复合物和凝血因子IX复合物抑制。
适应症
○非瓣膜性房颤患者缺血性脑卒中发作及全身性栓塞的发作抑制
○治疗静脉血栓栓塞(深静脉血栓形成和肺血栓栓塞)和抑制复发
○进行下肢骨科手术的患者静脉血栓栓塞发作的抑制
全膝关节置换手术,全髋关节置换手术,髋部骨折手术
用法与用量
○非瓣膜性房颤患者缺血性脑卒中发作及全身性栓塞的发作抑制
成人,以下剂量每天口服一次。
重量60公斤以下:30毫克
称重超过60公斤:60毫克根据肾功能和伴随药物,每天减少至30毫克。
○治疗静脉血栓栓塞(深静脉血栓形成和肺血栓栓塞)和抑制复发
成人,以下剂量每天口服一次。
重量60公斤以下:30毫克
称重超过60公斤:60毫克根据肾功能和伴随药物,每天减少至30毫克
○进行下肢骨科手术的患者静脉血栓栓塞发作的抑制
全膝关节置换手术,全髋关节置换手术,髋部骨折手术
成人,每天接受口服剂量30mg。
制造厂商
第一三共有限公司
Facebook Comments